Earned, Owned and Social Media Analytics Leaders Partner To Help Companies Understand The Business Impact of Content
2.2.2021 19:54:00 EET | Business Wire | Press release
Onclusive, the data science company for communications, and Shareablee, the social media analytics and competitive benchmarking company, today announced their strategic partnership to offer marketing and communications teams best-in-class solutions for earned, owned and social media insights. The partnership will help companies gain more holistic data about the performance of their owned and earned content across global news outlets, influencers and social media platforms.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210202005915/en/
Click to Tweet: Just announced: @Onclusive and @Shareablee partner to help companies measure the business impact of earned, owned, and social media marketing - through to revenue! https://bit.ly/39DF9xE #socialmediamarketing #prmeasurement
Social media, communications, public relations, and marketing teams each have a view of a company’s brand, reputation, and influence. Companies are increasingly looking to measure their owned and earned media strategies in a more centralized way by combining these functions within integrated teams and equipping them with comparable tools.
Particularly during times of crisis or uncertainty when companies put their emphasis on the tactics they can more closely control, social media amplification and paid media activation become even more important, as does measurement of the business impact of these efforts. The intersection between the data and solutions from Onclusive and Shareablee will provide organizations with more comprehensive content marketing data to better optimize their strategies.
Both Onclusive and Shareablee have their roots in enterprise media monitoring and content measurement and support Fortune 100 companies and their agencies. Both companies also recently launched mid-market products to deliver their data, platforms and services to a wider range of organizations.
“Social media strategies are fundamental to a company’s marketing plan, yet there is still more to the story. We are excited to be able to complete the picture for our clients via our relationship with Onclusive,” said Tania Yuki, CEO of Shareablee.
“We’ve always viewed our data and platforms as a bridge between communications teams and marketing teams. By working with Shareablee, our joint clients will be even better equipped to plan and execute harmonious cross-functional brand and communications strategies,” said Dan Beltramo, CEO of Onclusive.
About Onclusive
Onclusive is the data science company for communications. The inventors of PR Attribution™ and Power of Voice™, Onclusive measures the true impact that content is having on a company’s bottom line. The Onclusive platform is built upon a proprietary newscrawler which analyzes millions of earned, owned, and newswire articles every day globally and in over 100 languages, organizing each piece of content based on dozens of dimensions for aggregate and entity-level analysis.
The world’s leading brands and agencies including Airbnb, H&R Block, Lyft, Intercontinental Hotels Group, 23andMe, and Experian use Onclusive to modernize communications. For more information, visit onclusive.com and follow us on Twitter, LinkedIn, and Facebook.
About Shareablee
Shareablee is the leader in audience-based social media measurement for media publishers, agencies and brands that want to understand the impact and effectiveness of their cross-platform social media campaigns. Launched in 2013, Shareablee empowers brands by providing data that can help them define and drive success on social media by arming them with metrics and predictive analytics that inform powerful best practices. Shareablee is the leading authority on audience intelligence, competitive benchmarking and actionable insights with clients in 15+ countries.
For more information about Shareablee, visit shareablee.com and follow us on Twitter, LinkedIn, and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210202005915/en/
Contact information
Onclusive Contact:
Sean O'Neal
+1 415-906-5938
info@onclusive.com
Shareablee Contact:
Madison Busick
+1 508-868-4461
marketing@shareablee.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom